NEW YORK, March 30, 2017 /PRNewswire/ --
NetworkNewsWire Editorial Coverage
To date, it is estimated that the annual national cost of pain is between $560 billion and $635 billion - more than priority health conditions among the nation. Sadly, the treatment of postoperative pain remains a daunting challenge for health care professionals, leaving patients debilitated in ways that can affect their daily functioning and, in turn, have a significant impact on our nation's overall productivity. At present, patients face a significant disadvantage when using opioid drugs to treat postoperative and chronic severe pain, and usage thereof can lead to impactful side effects such as nausea, hallucinations, respiratory depression, constipation, and sedation.
While opioids have been widely accepted as a standard therapy to treat acute post-operative pain, the frequent adverse effects and burden of the cost of care has proven to be a barrier for patients who are unable to receive optimal dosing or adhered to their prescribed treatment. The administration of two opioids is not usually recommended as a treatment for moderate to severe acute pain; however, cannabis-based combination therapies present a unique opportunity in the health sector. Cannabis pharma company India Globalization Capital (IGC) has carved an impressive course in the combination therapy market as a 'first mover' to combine existing drugs with cannabis. IGC recently filed a patent for a formulation that the company claims will reduce the side effects of single drugs, by combining them with a cannabinoid. In particular, IGC has filed for a provisional patent for the treatment of several eating disorders that uses a combination of compounds and cannabis extracts. The combo therapy is ear-marked for both veterinary and human consumption.
After three years of building a sturdy IP portfolio, IGC is now set to obtain funding to begin both, pre-clinical and clinical trials for combination therapies, for which it has started reviewing international medical facilities. Fortunately, securing FDA approval for such therapies, which include the treatment of seizures, neuropathic pain and eating disorders, tends to be swifter and less costly than applying for new drug approval. It is the company's aim to leverage its unique first-mover position and bring its cannabis-based pharmaceuticals to market, in a cost-effective and prompt manner.
Meanwhile, Pacira Pharmaceuticals (NASDAQ: PCRX), which is collaborating with Trinity Health to develop an alternative approach to opioids for pain management, recently announced positive results for its medication for opioid reduction in a phase 4 clinical trial. During the trial, a pain regimen along with EXPAREL® was tested against a bupivacaine-based pain regimen that involved other drugs in 139 patients who were undergoing knee replacements. EXPAREL currently used to produce postsurgical analgesia, combines bupivacaine with the DepoFoam® platform, to enable the delivery of bupivacaine over a desired period of time, providing significant reductions in pain with up to a 45 percent decrease in opioid consumption.
In the phase 4 clinical trial, EXPAREL achieved statistical significance for its co-primary endpoints for postsurgical pain and opioid reduction, as well as achieved statistical significance for key secondary endpoints. In a press release announcing the results, Pacira said it continues to analyze further secondary endpoints.
Cara Therapeutics (NASDAQ: CARA) is also working to change pain management on a fundamental level. Rather than concentrating on improving old compounds, the company is developing a new class of medicine referred to as KORAs - Kappa Opioid Receptor Agonists. This medication is aimed at targeting different receptors in the body, to treat pain in an unconventional, yet more effective, manner. Up to now, Cara's core product has shown favorable results in phase 2 clinical trials for pain relief, and does not elicit the usual side effects patients would normally experience when using opioids such as hydrocodone, morphine, and non-steroidal anti-inflammatories.
Two more candidates for combination therapies come from Zynerba Pharmaceuticals (NASDAQ: ZYNE). ZYN001 and ZYN002 are both being evaluated in various therapeutic indications at the moment. ZYN001, a pro-drug patch that comprises of THC, is aimed at enabling transdermal delivery via a person's skin and into their circulatory system. ZYN002, a CBD gel, is the first of its kind and is designed to act as a non-psychoactive cannabinoid. The gel is to be delivered via the skin and absorbed into a patient's circulatory system. At present, the gel is in phase 2 of clinical development, with patients who suffer with osteoarthritis of the knee, refractory epilepsy, and Fragile X Syndrome.
Focused on the development and commercialization of innovative therapies that improve the quality of life of patients, Insys Therapeutics (NASDAQ: INSY) is developing a pipeline of products intending to address unmet medical needs and clinical shortcomings of existing commercial products. The Drug Enforcement Agency recently issued a provisional final ruling that is to result in Insys' SYNDROS™ being placed in Schedule II of the Controlled Substances Act. The product has been designed for chemotherapy patients and is aimed at helping to alleviate vomiting and nausea. It is also aimed at helping AIDS patients suffering from anorexia-type weight loss.
To date, there are some 53 million outpatients and 45 million inpatient surgeries that are performed in the United States annually. These surgeries necessitate drugs for postoperative pain, and more than half of postoperative patients continue to experience poor pain relief. At present, the therapeutic classes for postoperative pain management involve analgesics such as hydromorphone, morphine, and fentanyl, as well as NSAIDs - non-steroidal anti-inflammatories. Furthermore, the market is awash with injectable opioids that are administered either via epidural, intravenous, intrathecal, or intramuscular. Usually, the injections are administered either by patient-controlled analgesia devices or hospital personnel.
It has been found that the market for effective acute pain management, in the form of combined therapies outside of the hospital setting, exceeds more than 200 million prescriptions yearly. While products such as opioid analgesic combinations make up the bulk of the market, the products have significant side-effects, including sedations, dizziness, respiratory problems, substance abuse, euphoria, vomiting, and nausea. Hence, there is a vast market for combined therapies that are able to manage acute pain, without producing the negative and uncomfortable side effects.
For more information on India Globalization Capital please visit India Global Capital (IGC).
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is a source of content listed above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer or comparison to the profiled issuer. FN Media Group, LLC (FNM), is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker-dealer/analyst/adviser, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. NNW's compensation disclosure is incorporated herein and appears in full at http://NNW.fm/Disclaimer
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW & FNM undertakes no obligation to update such statements.
Media Contact E-mail: [email protected] FN Media Group, LLC Phone: (954)345-0611
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All